SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Claeys M)
 

Sökning: WFRF:(Claeys M) > (2010-2014) > Outcome and causes ...

Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients : Results from the PLATelet inhibition and patient Outcomes (PLATO) study

Åkerblom, Axel (författare)
Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi
Wallentin, Lars (författare)
Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi
Siegbahn, Agneta (författare)
Uppsala universitet,Koagulation och inflammationsvetenskap
visa fler...
Becker, R. C. (författare)
Budaj, A. (författare)
Horrow, J. (författare)
Husted, S. (författare)
Katus, H. (författare)
Claeys, M. J. (författare)
Storey, R. F. (författare)
Åsenblad, Nils (författare)
Uppsala universitet,Uppsala kliniska forskningscentrum (UCR)
James, Stefan K. (författare)
Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi
visa färre...
 (creator_code:org_t)
Elsevier BV, 2012
2012
Engelska.
Ingår i: American Heart Journal. - : Elsevier BV. - 0002-8703 .- 1097-6744. ; 164:5, s. 728-734
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Background: To investigate if ticagrelor treatment and other clinical characteristics were associated with increased cystatin C concentrations and if a deterioration in estimated renal function was associated with worse outcome in patients with acute coronary syndromes (ACS). Methods: Plasma cystatin C concentrations were determined within 24 hours of admission (baseline), at discharge, 1 month, and 6 months in the PLATO trial. The changes over time in relation to randomized treatment were analyzed by analysis of covariance. C-statistics and the relative Integrated Discrimination Improvement of the cystatin C concentrations regarding the primary outcome (cardiovascular death or myocardial infarction) was evaluated by multivariable analysis including background characteristics and biomarkers: N-terminal-pro-B-type natriuretic peptide and Troponin I. Results: Mean cystatin C concentrations in 2133 ticagrelor- and 2162 clopidogrel-treated patients were at baseline (0.86 mg/L and 0.86 mg/L), discharge (1.01 mg/L and 0.98 mg/L) (P <.0005), 1 month (1.00 mg/L and 0.98 mg/L) (P =.12), and 6 months (1.00 mg/L and 0.99 mg/L) (P =.17), respectively. Age, heart failure, and type of ACS were major determinants of the cystatin C concentration. c Statistics and the relative Integrated Discrimination Improvement of the primary outcome for the baseline cystatin C concentration were 0.687 and 5.2%, compared to 0.684 and 4.5% at discharge (n = 4034) and 0.693 and 5.1% at one month (n = 3096), respectively. Conclusions: Mean cystatin C concentrations increased in ACS patients, most importantly determined by age. The initial greater increase in ticagrelor-treated patients was not sustained over time. Risk prediction did not improve with serial measurements of renal markers.

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy